| Literature DB >> 32435069 |
Mario Marx1,2, Michael Geßner1, Alexander Florek1, Susanne Morgenstern1, Stefan Passin1, Sara Y Brucker2, Diethelm Wallwiener2, Markus Hahn2.
Abstract
Introduction Scarring and volume reduction of the axillary space resulting in persistent lymphedema is a side effect of axillary treatment in breast cancer patients. The aim of this paper is to describe the reduction of lymphedema achieved with a turnover flap. Materials and Methods Between October 2016 and May 2018, five patients with grade 2 lymphedema following breast cancer therapy underwent reconstructive surgery with a turnover flap. Complete excision of the symptomatic axillary scar tissue followed by re-augmentation using a turnover flap was performed. Subsequently, all patients underwent breast reconstruction using a distant flap reconnected to the thoracodorsal vessels. The circumference of both arms, quality of life and pain were measured before and after surgery. Results An average reduction in pain in the ipsilateral arm from 6 to 1 on the numerical scale as well as an improvement in quality of life (2.8 vs. 7.0) was observed. A decrease in lymphedema especially in the upper arm was identified. No complications such as secondary bleeding, infections or flap loss were observed. Conclusion Complete removal of the axillary scar tissue after breast cancer treatment and re-augmentation of the axilla with a turnover flap results in a reduction in ipsilateral lymphedema and an improvement in pain and quality of life. We interpret these findings as a result of the physiological re-alignment of the lymphatic vessels combined with a lymph node-containing local transposition flap. Therefore, re-augmentation with a turnover flap could be an effective non-microsurgical alternative to lymph node transplantation.Entities:
Keywords: axillary node; breast cancer; breast cancer-related lymphedema; lymph node transplantation; lymphedema
Year: 2020 PMID: 32435069 PMCID: PMC7234824 DOI: 10.1055/a-1063-6310
Source DB: PubMed Journal: Geburtshilfe Frauenheilkd ISSN: 0016-5751 Impact factor: 2.915
Fig. 1Schematic figure of lymph vessel kinking due to the poorly developed tunica media as a result of scar tissue development following axillary clearance.
Table 1 Summary of demographic data of our five patients as well as evaluation of pre- and postoperative pain and quality of life.
| LYMQOL-Score: the four domains are: function (Q1–3), appearance (Q4–8), symptoms (Q9–14) and mood (Q15–20). Each item score ranges from 1 (not at all) to 4 (a lot). | ||||||
| Patient | 1 | 2 | 3 | 4 | 5 | |
| Age | 59 | 50 | 43 | 59 | 48 | |
| BMI (kg/m 2 ) | 24.7 | 36.5 | 25.9 | 31.8 | 24.22 | |
| Lymphedema grade | Grade 2 | Grade 2 | Grade 2 | Grade 2 | Grade 2 | |
| Previous treatment | Mastectomy and axillary dissection | Mastectomy and axillary dissection | SSM and sec. axillary dissection | BCT and axillary dissection, SSM (recurrence disease) | SSM and axillary dissection | |
| Date of first diagnosis | 01/2008 | 11/2012 | 08/2014 | 1992 | 11/2013 | |
| TNM-Staging | pT3 pN0 (0/21 LK) M0 L1 G3 R1 | pT2 pN1a (2/20 LK) M0 V0 L1 G2 R0 | ypT0 ypN1a (1/7 LK) cM0 yL0 yV0 G3 R0 | pT2 pN0 (0/8 LK) M0, rpT1b pN0 (0/4) M0 L0 V0 G2 R0 | pT1c pN2 (6/10 LK) M0 V0 L1 G2 R0 | |
| Receptor status | ER: IRS = 12 | ER: IRS = 12 | ER: IRS = 6 | ER: IRS = 2 | ER: IRS = 9 | |
| Systemic therapy | Adjuvant (3 × FEC, 3 × docetaxel), endocrine therapy: tamoxifen | Adjuvant (6 × TAC), endocrine therapy: tamoxifen | Neoadjuvant (3 × FEC, 3 × docetaxel) and trastuzumab, endocrine therapy: tamoxifen | Adjuvant (4 × EC, 12 × Taxol), endocrine therapy: tamoxifen | Adjuvant (4 × EC, 12 × Taxol), endocrine therapy: tamoxifen | |
| Radiotherapy | Thoracic wall and axilla + supraclavicular (68,4 Gy) | Thoracic wall and axilla (50,4 Gy) | Thoracic wall and axilla | whole-breast irradiation with boost | Thoracic wall and axilla + supraclavicular (50,4 Gy) | |
| Date of turn-over flap | 05/2016 | 08/2016 | 11/2016 | 09/2017 | 11/2017 | |
| Pain score (NAS0 – 10) | Pre-op. | 8 | 5 | 8 | 2 | 7 |
| Post-op. | 1 | 0 | 3 | 1 | 0 | |
| Lymphedema treatment | Pre-op. | Yes | Yes | Yes | Yes | Yes |
| Post-op. | No | limited time only | limited time only | No | No | |
| LYMQOL-score | Pre-op. | 63 | 64 | 74 | 47 | 48 |
| Post-op. | 49 | 41 | 64 | 44 | 30 | |
| Quality of life (0 = very poor to 10 = very good) | Pre-op. | 2 | 3 | 2 | 3 | 4 |
| Post op. | 7 | 8 | 5 | 7 | 8 | |
Fig. 2Preoperative site.
Fig. 3Incised turnover flap before transposition into the axillary region for re-augmentation of the volume deficit following scar tissue excision.
Fig. 4Surgical site 6 weeks postoperatively.
Fig. 5Lymphatic perfusion after preoperative injection of indocyanine green using an infrared camera.